Intrahepatic cholestasis of pregnancy

From WikiProjectMed
(Redirected from Cholestasis of pregnancy)
Jump to navigation Jump to search
Intrahepatic cholestasis of pregnancy
Other names: Obstetric cholestasis; cholestasis of pregnancy; jaundice of pregnancy; prurigo gravidarum[1] icterus gravidarum[2]
High magnification micrograph showing liver cholestasis
SpecialtyObstetrics
SymptomsItchy skin, no initial rash[3]
ComplicationsBaby: Premature birth, meconium aspiration syndrome, intrauterine death[3]
Mother: Gallstone disease, vitamin K deficiency[2]
Usual onsetThird trimester[2]
DurationResolves within 2 weeks after delivery[2]
Risk factorsFamily history, twin pregnancy[2]
Diagnostic methodBased on symptoms and bile acid levels[2][3]
Differential diagnosisPemphigus gestationis, prurigo of pregnancy, polymorphic eruption of pregnancy, scabies, pre-eclampsia[2]
PreventionSelenium supplementation[2]
TreatmentDelivery at 36 to 38 weeks, ursodeoxycholic acid, antihistamines[3][2]
Frequency0.1% to 1.5% of pregnancies (Western world)[2]

Intrahepatic cholestasis of pregnancy (ICP), also known as jaundice of pregnancy, is a skin condition of pregnancy that results in itchy skin.[3] Itchiness is often severe, particularly at night, and while there is typically no initial rash, skin breakdown may occur due to scratching.[4] Other symptoms may include a yellow color and right upper abdominal discomfort.[3][2] Onset is typically in the third trimester; though occasionally may occur earlier.[2]

Risk factors include genetics, with half of people having a family history, and twin pregnancy.[2] The underlying mechanism involves liver problems, known as cholestasis, as a result of high levels of hormones.[2] Diagnosis is based on symptoms and bile acid levels greater than 10 μmol/L (4.08 mcg/mL) in the blood.[2][3]

Selenium supplementation may decrease its occurrence.[2] Management may involved delivery at 36 to 38 weeks.[2] Ursodeoxycholic acid may improve outcomes.[2] Antihistamines may be used.[3] Complications for the baby may include premature birth, meconium aspiration syndrome, and intrauterine death.[3] Complications for the mother may include gallstone disease and vitamin K deficiency.[2] While it typically goes away within 2 weeks after delivery, it often recures in subsequent pregnancies.[2]

Intrahepatic cholestasis of pregnancy affects between 0.1 and 1.5% of pregnancies in much of the Western world.[2] Rates in Bolivia are around 9% and in certain populations in Chile are 28%.[2] In more commonly occurs in winter months.[2] The condition was first described by Ahlfeld in 1883.[5]

Signs and symptoms

Most women with this condition present in the third trimester (although it can present as early as seven weeks) with itching without a rash. Typically, the itching is localized to the palms of the hands and soles of the feet, but can be anywhere on the body.

Symptoms include:

Most common:

  • Itching, in particular but not limited to that of the palms of the hands and soles of the feet, without presence of a rash
  • Itching that is more noticeable in the evening
  • Darker urine

Less common:

  • Lighter stools
  • Increased clotting time (due to possibly associated vitamin K deficiency)
  • Fatigue
  • Increased nausea
  • Decrease in appetite
  • Jaundice (less than 10% of women)
  • Upper right quadrant pain

Not all ICP sufferers have all of the above symptoms.

Complications

Maternal consequences include the following:

  • Itching, which can become intense and debilitating
  • Spontaneous premature labour when bile acids rise above 40 μmol/litre[6]

Fetal consequences include:

  • Fetal distress
  • Meconium ingestion
  • Stillbirth

In most cases induction is typically recommended anywhere from 34–39 weeks.[7][8][9][10][11][12] In the United States, some researchers have suggested that the risk of stillbirth is lower if induction occurs at 36 weeks. Whilst Ovadia's research[7] suggests differently, it is important to note that in the United States bile acid tests can take up to seven days to be processed, and this means that it may be more prudent to base delivery on the US research.[13]

Mechanism

PPARγ/NF-κB signaling pathway in the pathogenesis of intrahepatic cholestasis of pregnancy (a,d-control)

The causes of intrahepatic cholestasis of pregnancy are not fully understood, but are thought to be caused through a combination of genetics,[14][15] hormones and environment.[16] Hormones, environmental and genetic factors are all thought to contribute to the condition.[17]

Estrogen

Estrogens, and particularly glucuronides such as estradiol-17β-D-glucuronide, have been shown to cause cholestasis in animal studies, by reducing bile acid uptake by hepatocytes.[19]

Progesterone

Treatment with progesterone in the third trimester of pregnancy has been shown to be associated with the development of ICP, and levels of metabolites of progesterone, particularly sulfated progesterone,[20] are higher in patients with ICP than unaffected women, suggesting that progesterone may have a bigger role than estrogen in ICP.[21]

Genetics

Clustering of cases of ICP in families, geographic variation in rates of ICP, and recurrence of ICP in 45-70% of subsequent pregnancies all suggest a genetic component to the disease.[17] Genetic mutations in the hepatocellular transport protein ABCB4 (MDR3), which controls secretion of phosphatidylcholine into bile, have been found in cases of ICP.[22]

Genetic mutations affecting hepatic bile salt transport molecules have also been found in patients with progressive familial intrahepatic cholestasis. It has been found that mothers of patients with this disease have a higher incidence of ICP, suggesting that heterozygote carriers of these mutations are also predisposed to ICP.[17]

In addition to genetic changes to bile salt transport molecules, high levels of estrogen glucuronides have been shown to inhibit the bile salt export pump (BSEP) ABCB11,[23] and high levels of progesterone to inhibit the ABCB4 (MDR3) phospholipid transporter.[24]

Consequently, both genetic mutations in hepatocyte proteins involved in bile secretion together with inhibition of those proteins by high levels of hormone metabolites in pregnancy may have roles in the pathogenesis of ICP.[16]

Environmental

A number of features of ICP suggest that environmental factors also have a role in the disease:

  • It has been reported that the incidence of ICP is higher in winter than summer.[25]
  • The incidence of ICP in Chile has dropped from 14% of pregnancies before 1975 to 4% in 2016.[26]
  • ICP recurs in between 60% and 90% of subsequent pregnancies.
  • Low serum selenium levels have been linked to ICP,[27] although the role of selenium in bile secretion is not known.

Diagnosis

ICP is diagnosed by blood tests including a serum bile acid test and liver function test. While most pregnant women experience some itch from time to time, itching without a visible rash, or persistent or extensive itch symptoms should be reported to the midwife or obstetrician. It is important to note that as the level of itch does not correlate with bile acid levels (shown to be the most likely cause of stillbirth in ICP), the itch in ICP can range from being mild to severe.

To obtain a diagnosis of ICP, a liver function test and a serum bile acid test should be requested. Although the ALT level may be raised, 20% of women with ICP will always have a normal LFT test result.[28] This, plus pruritus of palms and soles, could be considered as potentially diagnostic of ICP but only with elevated bile acid levels (however LFTs are not always elevated in ICP patients). The serum bile acid blood test for ICP is a quantitative measurement of bile acids.

Other problems with the liver that occur in pregnancy should be considered by the treating clinician. These include preeclampsia, the HELLP syndrome, and acute fatty liver of pregnancy. Furthermore, other causes of hepatitis, like hepatitis viruses, cancer and certain medications, should also be considered.

Treatment

Many providers will prescribe ursodeoxycholic acid. The most recent trial, PITCHES,[29] did not show an overall beneficial effect, but some researchers believe that it may still be useful to offer ursodeoxycholic acid to women whose bile acids are > 40 μmol/litre. While there is no cure for ICP, and no way to guarantee a successful outcome, studies have shown a slightly better fetal and maternal outcome from administration of ursodeoxycholic acid, whereas cholestyramine appears to only relieve itching.[19][30]

There is no evidence that giving oral water-soluble Vitamin K may help to avoid the risk of hemorrhage at delivery. However, experts in ICP will prescribe this if the woman reports pale stools, has very severe ICP (bile acids > 100 μmol/litre) or has a known clotting problem.

Delivery from 34 weeks may be important to reduce the risk of stillbirth, as a recent study identified the level of bile acids at which stillbirth risk rises. This research, published in The Lancet, also suggests that around 90% of women with ICP could wait until 39 weeks of pregnancy to be induced. However, this relies on regular bile acid testing with rapid return of results.[7]

See also

References

  1. ↑ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 Roth, MM (1 February 2011). "Pregnancy dermatoses: diagnosis, management, and controversies". American journal of clinical dermatology. 12 (1): 25–41. doi:10.2165/11532010-000000000-00000. PMID 21110524.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Tunzi M, Gray GR (January 2007). "Common skin conditions during pregnancy". American Family Physician. 75 (2): 211–8. PMID 17263216.
  4. ↑ Saavedra, Arturo; Roh, Ellen K.; Mikailov, Anar (2023). "15. Endocrine, metabolic, and nutritiona". Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 9/e (9th ed.). New York: McGraw Hill Professional. pp. 414l. ISBN 978-1-264-27801-5. Archived from the original on 2023-12-31. Retrieved 2023-12-29.
  5. ↑ Geenes, V; Williamson, C (7 May 2009). "Intrahepatic cholestasis of pregnancy". World journal of gastroenterology. 15 (17): 2049–66. doi:10.3748/wjg.15.2049. PMID 19418576.
  6. ↑ Glantz, A; Marschall, HU; Mattsson, LA (2004). "Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates". Hepatology. 40 (2): 467–474. doi:10.1002/hep.20336. PMID 15368452. S2CID 44954417. Archived from the original on 29 October 2020. Retrieved 26 October 2020.
  7. ↑ 7.0 7.1 7.2 Ovadia, Caroline (2019). "Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses". Lancet. 393 (10174): 899–909. doi:10.1016/S0140-6736(18)31877-4. PMC 6396441. PMID 30773280. S2CID 72333644. Archived from the original on 2022-03-29. Retrieved 2022-03-10.
  8. ↑ Geenes V, Williamson C (2009). "Intrahepatic Cholestasis of pregnancy". World Journal of Gastroenterology. 15 (17): 2049–2066. doi:10.3748/wjg.15.2049. PMC 2678574. PMID 19418576.
  9. ↑ Fisk NM, Storey GN: "Fetal outcome in obstetric cholestasis. Br J Obstet Gynaec 1988;95:1137- 1143.
  10. ↑ Zecca E, Costa S, Lauriola V; et al. (2003). "Bile acid pneumonia: A "new" form of neonatal respiratory distress syndrome?". Pediatrics. 114 (1): 269–272. doi:10.1542/peds.114.1.269. PMID 15231944.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ↑ Shaw D, Frohlich J, Wittmann BA, Willms M (1982). "A prospective study of 18 patients with cholestasis of pregnancy". Am J Obstet Gynecol. 142 (6): 621–625. doi:10.1016/s0002-9378(16)32430-9. PMID 7065033.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ↑ Davies MH, Silva RC, Jones SR; et al. (1995). "Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid". Gut. 37 (4): 580–584. doi:10.1136/gut.37.4.580. PMC 1382915. PMID 7489950.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ↑ Puljic A, Kim E, Page J; et al. (2015). "The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age". Am J Obstet Gynecol. 212 (5): 667.e1–5. doi:10.1016/j.ajog.2015.02.012. PMID 25687562.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Dixon, PH; Wadsworth, CA; Chambers, J; Donnelly, J; Cooley, S; Buckley, R; Mannino, R; Jarvis, S; Syngelaki, A; Geenes, V; Paul, P; Sothinathan, M; Kubitz, R; Lammert, F; Tribe, RM; Ch'ng, CL; Marschall, HU; Glantz, A; Khan, SA; Nicolaides, K; Whittaker, J; Geary, M; Williamson, C (2014). "A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy". American Journal of Gastroenterology. 109 (1): 76–84. doi:10.1038/ajg.2013.406. PMC 3887577. PMID 24366234.
  15. ↑ Dixon, PH; Sambrotta, M; Chambers, J; Taylor-Harris, P; Syngelaki, A; Nicolaides, K; Knisely, AS; Thompson, RJ; Williamson, C (2017). "An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy". Scientific Reports. 7 (1): 11823. doi:10.1038/s41598-017-11626-x. PMC 5603585. PMID 28924228.
  16. ↑ 16.0 16.1 Pusl T, Beuers U (2007). "Intrahepatic cholestasis of pregnancy". Orphanet Journal of Rare Diseases. 2: 26. doi:10.1186/1750-1172-2-26. PMC 1891276. PMID 17535422.
  17. ↑ 17.0 17.1 17.2 Lammert F, Marschall HU, Glantz A, Matern S (December 2000). "Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management". J. Hepatol. 33 (6): 1012–21. doi:10.1016/S0168-8278(00)80139-7. PMID 11131439.
  18. ↑ Gonzalez MC, Reyes H, Arrese M, et al. (July 1989). "Intrahepatic cholestasis of pregnancy in twin pregnancies". Journal of Hepatology. 9 (1): 84–90. doi:10.1016/0168-8278(89)90079-2. PMID 2768798.
  19. ↑ 19.0 19.1 Reyes H, Sjövall J (March 2000). "Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy". Annals of Medicine. 32 (2): 94–106. doi:10.3109/07853890009011758. PMID 10766400. S2CID 25925651.
  20. ↑ Abu-Hayyeh, S (2015). "Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum". Hepatology. 63 (4): 1287–1298. doi:10.1002/hep.28265. PMC 4869673. PMID 26426865.
  21. ↑ Abu-Hayyeh, S; Ovadia, C; Lieu, T; Jensen, DD; Chambers, J; Dixon, PH; Lovgren-Sandblom, A; Bolier, R; Tolenaars, D; Kremer, AE; Syngelaki, A; Noori, M; Williams, D; Marin, JJG; Monte, MJ; Nicolaides, KH; Beuers, U; Oude-Elferink, R; Seed, PT; Chappell, L; Marschall, H-U; Bunnett, NW; Williamson, C (2016). "Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum". Hepatology. 63 (4): 1287–1298. doi:10.1002/hep.28265. PMID 26426865. S2CID 20203783. Archived from the original on 29 October 2020. Retrieved 26 October 2020.
  22. ↑ Dixon, PH (2017). "An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy". Scientific Reports. 7 (1): 11823. Bibcode:2017NatSR...711823D. doi:10.1038/s41598-017-11626-x. PMC 5603585. PMID 28924228.
  23. ↑ Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ (2000). "Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver". Gastroenterology. 118 (2): 422–30. doi:10.1016/S0016-5085(00)70224-1. PMID 10648470.
  24. ↑ Debry P, Nash EA, Neklason DW, Metherall JE (January 1997). "Role of multidrug resistance P-glycoproteins in cholesterol esterification". Journal of Biological Chemistry. 272 (2): 1026–31. doi:10.1074/jbc.272.2.1026. PMID 8995398.
  25. ↑ Williamson, Catherine; Geenes, Victoria (2014). "Intrahepatic cholestasis of pregnancy". Obstetrics and Gynecology. 124 (1): 120–33. doi:10.1097/AOG.0000000000000346. PMID 24901263. S2CID 9986882. Archived from the original on 2022-03-29. Retrieved 2022-03-10.
  26. ↑ Ovadia, Caroline; Williamson, Catherine (2016). "Intrahepatic cholestasis of pregnancy: recent advances". Clinics in Dermatology. 34 (3): 327–34. doi:10.1016/j.clindermatol.2016.02.004. PMID 27265070. Archived from the original on 2022-03-29. Retrieved 2022-03-10.
  27. ↑ Kauppila A, Korpela H, Mäkilä UM, Yrjänheikki E (January 1987). "Low serum selenium concentration and glutathione peroxidase activity in intrahepatic cholestasis of pregnancy". British Medical Journal (Clinical Research Edition). 294 (6565): 150–2. doi:10.1136/bmj.294.6565.150. PMC 1245162. PMID 3109544.
  28. ↑ Conti-Ramsden, F; McEwan, M; Hill, R; Wade, J; Abraham, G; Buckeldee, O; Williamson, C; Knight, CL; Girling, J; Chappell, LC (2019). "Detection of additional abnormalities or co-morbidities in women with suspected intrahepatic cholestasis of pregnancy". Obstetric Medicine. 13 (4): 185–191. doi:10.1177/1753495X19868873. PMC 7726172. PMID 33343695.
  29. ↑ Chappell, LC; Chambers, J; Dixon, PH; Dorling, J; Hunter, R; Bell, JL; Bowler, U; Hardy, P; Juszczak, E; Linsell, L; Rounding, C; Smith, C; Williamson, C; Thornton, JG (2019). "Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES)". Lancet. 394 (10201): 849–860. doi:10.1016/S0140-6736(19)31270-X. PMC 6739598. PMID 31378395.
  30. ↑ Walker, Kate F.; Chappell, Lucy C.; Hague, William M.; Middleton, Philippa; Thornton, Jim G. (27 July 2020). "Pharmacological interventions for treating intrahepatic cholestasis of pregnancy". The Cochrane Database of Systematic Reviews. 7: CD000493. doi:10.1002/14651858.CD000493.pub3. ISSN 1469-493X. PMC 7389072. PMID 32716060.

External links

Classification
Retrieved from "https://mdwiki.org/w/index.php?title=Intrahepatic_cholestasis_of_pregnancy&oldid=1392411"